

Press release 2015-09-08

WntResearch presents Foxy-5 at oncology conference

WntResearch announces that an abstract presenting data on Foxy-5 has been accepted for presentation at a major international meeting in Boston at November 6.

WntResearch has received acceptance on an abstract presentation of results from their preclinical and clinical studies with Foxy-5 at the joint meeting of AACR-NCI-EORTC* International Conference on Molecular Targets and Cancer Therapeutics, November 5-9 in Boston, Massachusetts, USA. The presentation will be a poster: *"Targeting the Wnt-5a signalling pathway as a novel anti-metastatic therapy"* and it will be presented on Friday November 6, between 12:15-3:15.

CEO, Nils Brünner says: *"AACR-NCI-EORTC joint meeting is the most prominent international meeting on anti-cancer drug development. The meeting attracts representatives from almost all Pharma and biotech companies involved in cancer drug development. Obviously, this meeting makes an excellent opportunity for us to present our preclinical and clinical results on Foxy-5 and to initiate discussions with other interested researchers and companies. I am very pleased that WntResearch now gets this opportunity and we are looking forward to present our exiting results"*.

Session ID: Poster Session A

Session Title: Metastasis and Invasion

Session Date and Time: Friday Nov 6, 2015 12:15 PM - 3:15 PM

Location: Exhibit Hall C-D

Permanent Abstract Number: A116

*AACR-NCI-EORTC stands for American Association for Cancer Research, the National Cancer Institute in USA and the European Organization for Research and Treatment of Cancer.

For additional information please contact:

Nils Brünner, CEO

E-mail: nbr@wntresearch.com

Telephone: + 45 2614 4708

About WntResearch

WntResearch AB is a public company on the AktieTorget in Sweden. WntResearch develops the anti-cancer compound Foxy-5 to be used to combat the metastatic process of cancer. WntResearch has one drug candidate in clinical phase 1 – Foxy-5 – as well as one candidate drug in preclinical development – Box-5. The Company is currently focusing mainly on the development of Foxy-5.